We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Colin Kellaher Shares of Travere Therapeutics tumbled nearly 35% and hit a new 52-week low Tuesday after the biopharmaceutical company said a pivotal Phase 3 study of its kidney drug Filspari...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.12 | -0.400057151022 | 279.96 | 310.01 | 162.01 | 833709 | 272.24443022 | DE |
4 | -2.16 | -0.768683274021 | 281 | 310.01 | 162.01 | 611235 | 278.9656511 | DE |
12 | -16.16 | -5.47796610169 | 295 | 380.01 | 160.01 | 712708 | 284.43327027 | DE |
26 | 46.14 | 19.828104856 | 232.7 | 380.01 | 154 | 680951 | 275.07532782 | DE |
52 | -23.91 | -7.89760528489 | 302.75 | 380.01 | 152 | 749664 | 272.96850159 | DE |
156 | 10.82 | 4.03701216327 | 268.02 | 400 | 0.11 | 744318 | 280.52392855 | DE |
260 | 75.84 | 37.3596059113 | 203 | 400 | 0.11 | 798367 | 279.50969297 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions